<?xml version="1.0" encoding="UTF-8"?>
<p>In nCOVID-19 high-risk populations, traditional Chinese medicines were also regarded as a preventative measure, based on the traditional uses and anecdotal evidence of prevention of H1N1 pdm09 and SARS. Nonetheless, there is a lacking of clinical data regarding the effectiveness of these herbal medicines as an nCOVID-19 treatment (Cunningham et al., 
 <xref rid="B53" ref-type="bibr">2020</xref>; Luo et al., 
 <xref rid="B121" ref-type="bibr">2020</xref>). In China, several traditional medicines were widely used during the nCOVID-19 epidemic and 6 of these herbal medicines include Lianqiao (
 <italic>Fructus forsythia</italic>), Jinyinhua (Lonicerae Japonicae Flos), Gancao (Glycyrrhizae Radix Et Rhizoma), Baizhu (Atractylodis Macrocephalae Rhizoma, rhizome of 
 <italic>Atractylodes macrocephala</italic> Koidz), Fangfeng (Saposhnikoviae Radix, dried root from the perennial herb 
 <italic>Saposhnikovia divaricate</italic>), and Huangqi (Astragali Radix, dried root of 
 <italic>Astragalus membranaceus Bge</italic>. 
 <italic>Var</italic>. 
 <italic>mongholicus</italic>). Indeed, stringent clinical studies are required with a large number of participants to demonstrate the preventive role of these traditional Chinese medicines (Cunningham et al., 
 <xref rid="B53" ref-type="bibr">2020</xref>; Luo et al., 
 <xref rid="B121" ref-type="bibr">2020</xref>).
</p>
